Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$139.36M+1183.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Walter Hanna Jr.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 763
- Beta
- 2.49
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 13.45
Financials
Revenue
$139.36M+1183.3%Net Income
$19.29MEBITDA
$17.90MFree Cash Flow
$11.10MEPS (diluted)
$0.35Shares Outstanding (diluted)
54.98M+158.5%Operating Expenses
$90.96MCash & Debt
$250.48MReturn of Capital
$0.00Revenue by Segment (annual)
$322.87MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $379.81M | $-21.35M | $-0.40 |
| 2024 | $333.79M | $52.55M | $1.00 |
| 2023 | $280.32M | $-190.28M | $-3.54 |
| 2022 | $321.79M | $-76.61M | $-1.44 |
| 2021 | $296.40M | $-30.66M | $-0.59 |
| 2020 | $192.19M | $-18.71M | $-0.40 |
| 2019 | $127.07M | $-21.97M | $-0.52 |
| 2018 | $76.57M | $-46.76M | $-1.31 |
| 2017 | $48.32M | $-55.47M | $-2.38 |
| 2016 | $40.63M | $-39.47M | $-2.39 |
| 2015 | $28.14M | $-13.71M | $-1.16 |
| 2014 | $27.31M | $781.0K | $0.13 |
| 2013 | $22.10M | $-3.54M | $-0.48 |
| 2012 | $20.45M | $-5.06M | $-0.69 |
Valuation
CDNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30+0.00%Social Signal Score
Mentions (16)
- Newszacks.com·5d ago·Negative
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 28.1% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - News (RSS)zerohedge·11d ago·Neutral
…ngs per share of $1.08 for the third quarter.BrightView shares (BV) fall 18% after it forecast revenue for 2027 that missed the average analyst estimate.CareDx Inc. (CDNA) shares are up 2.9% after the stock was initiated at overweight by Piper Sandler, which cited the growth potential of the organ transplant services company.CoreWeave (CRWV) gains 15% in premarket trading after the cloud-computing provider boosts its annual revenue forecast, easing worries about the company’s financing.Globant s…
View source ↗ - News (RSS)investing·15d ago·Neutral
Cathie Wood’s ARK sells CareDx stock, buys Natera and Kratos
View source ↗ - Newsbusinesswire.com·16d ago·Negative
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock. The RSUs will …
View source ↗ - Newszacks.com·16d ago·Positive
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - News (Marketaux)seekingalpha.com·18d ago·Positive
Baron Discovery Fund Q3 2026 Commentary (BDFIX) Top Contributors & Detractors Top contr[+335 characters]
View source ↗ - Newszacks.com·19d ago·Negative
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth CDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.
View source ↗ - Newsfool.com·23d ago·Negative
Why CareDx Stock Soared Today CareDx is a leader in the fast-growing field of medical diagnostics. The company is working to bring its non-invasive tests to new markets.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Negative
What CareDx (CDNA) Said on Its Q3 Earnings Call CareDx NASDAQ: CDNA reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Naveris.
View source ↗ - Newszacks.com·24d ago·Neutral
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates CareDx (CDNA) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.28 per share a year ago.
View source ↗ - Newszacks.com·27d ago·Neutral
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
View source ↗ - Newszacks.com·58d ago·Negative
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newszacks.com·87d ago·Neutral
CareDx (CDNA) is a Great Momentum Stock: Should You Buy? Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·89d ago·Negative
Zacks Industry Outlook CareDx, BrightSpring and PACS CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
View source ↗ - Newsgurufocus.com·94d ago·Negative
Ron Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF Value On June 30, 2026, Ron Baron (Trades, Portfolio) executed a significant reduction in the firm's position in CareDx Inc (NASDAQ: CDNA), selling 1,399,083 shares at
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.33 per share
Typical surprise +138.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$0.70 vs $0.25beat
- Thu, Jul 30$0.37 vs $0.23beat
- Tue, Apr 28$0.34 vs $0.11beat
- Tue, Feb 24$0.12 vs $0.02beat
- Tue, Nov 4$0.03 vs $-0.08beat
- Wed, Aug 6$-0.16 vs $-0.10miss
Estimates and results for CDNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CDNA officers and directors.
- Bought
- —
- Sold
- $18.8m
0 trades
35 trades
- Goldberg Michaelsold
- Goldberg Michaelsold
- Goldberg Michaelsold
- Kennedy Keithsold
- Kennedy Keithsold
- Novack Jeffrey Adamsold
- Novack Jeffrey Adamsold
- Novack Jeffrey Adamsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Apr 10, 2021 (39d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (627d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (704d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (625d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (725d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
